Research Progress of Probiotics in the Adjuvant Therapy of Helicobacter pylori Infections

Abstract:

Helicobacter pylori (Hp) is a major pathogenic bacterium that infects the human stomach and can lead to various gastrointestinal disorders, including gastritis, gastric ulcers, and even gastric cancer. Currently, triple or quadruple therapy combining antibiotics with proton pump inhibitors or bismuth compounds is commonly used to treat Hp infections in clinical practice. However, the escalating antibiotic resistance of Hp has led to a gradual reduction in the effectiveness of antibiotic treatments, with monotherapy having an eradication rate of less than 80%. Recent studies have found that probiotics show promising results in the adjuvant therapy for Hp infections. They not only alleviate gastric inflammation caused by Hp but also enhance the eradication rate of Hp and reduce the side effects of antibiotic treatment. The author reviews the application of probiotics in the treatment of Hp infections, aiming to provide a reference for further research and clinical use of probiotics as an adjuvant therapy.